New approach targets hidden HIV inflammation to protect hearts
NCT ID NCT07030920
Summary
This study is testing whether adding a medication called fostemsavir to standard HIV treatment can lower the risk of heart disease in people whose HIV is already well-controlled. Researchers will compare heart scans, physical tests, and blood markers over two years between 150 participants who either receive the extra drug or continue their usual care. The goal is to see if blocking a specific HIV protein reduces harmful inflammation that can lead to heart problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK FACTOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CR CHUM
RECRUITINGMontreal, Quebec, H2X 0A9, Canada
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.